Cubist Pharmaceuticals (CBST) says the FDA has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product for the indications of Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections. Additionally, the FDA also granted the drugs Fast Track status for Complicated Intra-Abdominal Infections and Clostridium difficile-Associated Diarrhea. Shares +4% AH.
Cubist Pharmaceuticals (CBST) says the FDA has designated the company's late-stage antibiotic...
From other sites
Video at CNBC.com (Jul 1, 2016)
Video at CNBC.com (Jun 16, 2016)
Video at CNBC.com (Jun 6, 2016)
Video at CNBC.com (Jun 3, 2016)
Video at CNBC.com (May 5, 2016)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs